A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant Patients
Public ClinicalTrials.gov record NCT00106639. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 6-Month, Phase 2, Multicenter, Randomized, Open-Label, Comparative Study Of 2 Dose Levels Of CP-690,550 Administered Concomitantly With IL-2 Receptor Antagonist Induction Therapy, Mycophenolate Mofetil And Corticosteroids Versus A Tacrolimus-Based Immunosuppressive Regimen For The Prevention Of Allograft Rejection In De Novo Renal Allograft Recipients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2 study was designed to evaluate the safety and efficacy of 2 dose levels of CP-690,550 (15 mg twice daily and 30 mg twice) against tacrolimus, in combination with basiliximab induction, mycophenolate mofetil and corticosteroids, in kidney transplant patients. Stage 1 was to randomize approximately 54 subjects. After all Stage 1 subjects had completed 6 months of treatment, Stage 2 was to randomize an additional 195 subjects to the same treatment groups.
Study identification
- NCT ID
- NCT00106639
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 61 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2005
- Primary completion
- Jun 30, 2006
- Completion
- Jun 30, 2006
- Last update posted
- Mar 11, 2013
2005 – 2006
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Los Angeles | California | 90057 | — |
| Pfizer Investigational Site | Los Angeles | California | 92356 | — |
| Pfizer Investigational Site | Palo Alto | California | 94304 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | San Francisco | California | 94115 | — |
| Pfizer Investigational Site | San Francisco | California | 94143-0780 | — |
| Pfizer Investigational Site | Stanford | California | 94305 | — |
| Pfizer Investigational Site | Denver | Colorado | 80262 | — |
| Pfizer Investigational Site | Chicago | Illinois | 60611 | — |
| Pfizer Investigational Site | New Orleans | Louisiana | 70112 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110-1092 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63110 | — |
| Pfizer Investigational Site | Livingston | New Jersey | 07039 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | New York | New York | 10029 | — |
| Pfizer Investigational Site | Portland | Oregon | 97210 | — |
| Pfizer Investigational Site | Dallas | Texas | 75204 | — |
| Pfizer Investigational Site | Dallas | Texas | 75246 | — |
| Pfizer Investigational Site | Richmond | Virginia | 23298 | — |
| Pfizer Investigational Site | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00106639, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 11, 2013 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00106639 live on ClinicalTrials.gov.